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Abstract: This study aimed to determine the presence of giardiasis among HIV patients in San Diego,
the rate of failure of metronidazole treatment, and factors associated with treatment failure. We used a
7 year retrospective single-center case series of HIV-infected individuals with giardiasis at University
of California San Diego Medical Center. Data were analyzed for the changes in the hematological,
biochemical, and immunologic results at pre- and at-diagnosis levels. We also compared the changes
at the diagnosis level among patients who were treated successfully and those who experienced
treatment failure as defined by retreatment with a second course of antibiotics. In 29 Giardia
lamblia-infected HIV patients, following diagnosis of G. lamblia, there was a non-significant decrement
in cluster of differentiation 4 (CD4), but a statistically significant increase in the number of white
blood cell (WBC). Other indices did not differ between pre- and at-diagnosis levels. Twenty patients
(69%) were treated with a single course of metronidazole or tinidazole and seven patients (24.1%)
were treated with more than one course of metronidazole. These seven patients had statistically
significant higher hemoglobin at the time of diagnosis, but further studies are required to confirm if
this is a consistent finding and if this can predict failure from primary therapy.
Keywords: metronidazole; giardia; HIV; treatment failure; retrospective
1. Introduction
Almost two hundred million cases of giardiasis are reported each year worldwide [1] with an estimated
1.2 million in the US [2]. In developed countries, Giardia lamblia, the protozoan responsible for giardiasis,
infects about 2% of adults and approximately 6–8% of children [3,4]. The prevalence of giardiasis is higher
in developing countries [5]. According to the WHO Foodborne Disease Burden Epidemiology Reference
Group (FERG), giardiasis produced 171,100 disability-adjusted life years (DALYs) in 2010 [1]. In the US,
human giardiasis is the most common intestinal parasitic disease and the single most frequently identified
pathogen in all drinking water outbreaks from 1971 to 2006 with 121 outbreaks [4]. In 2010, the total number
of reported cases of giardiasis in the US was 19,927 [4]. Each year, hospitalizations resulting from giardiasis
cost approximately $34 million; additionally, each ambulatory care visit for giardiasis costs $121–$273 [5].
While the national incidence rate of giardiasis in 2016 was 6.4 cases per 100,000 persons, California reported
the incidence rate of 7 cases per 100,000 persons. On the other hand, San Diego County’s incidence rate
was 12.1 in 2016 [6]. The high rate in San Diego may be partially explained by a larger refugee population
since about 30% of giardiasis cases were reported from refugees, and the median age of these cases was 10
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years [6]. Among non-refugee cases, the median age was 37 years, and they were reported from travelers,
campers, and recreational water users but the number of HIV-infected patients was not reported [6]. There
was an imbalance by sex with 64% of giardiasis cases from San Diego were in males [6].
Because of its low infectious dose and potential for causing food and water outbreaks in the
United States, the National Institutes of Health (NIH) has listed G. lamblia as a category B priority
biodefense pathogen. In 2004, Giardia was included in the WHO Neglected Diseases Initiative due to
its link with poverty [7].
Metronidazole is the most common drug used to treat giardiasis [8]. It is cheap and has been in use for
more than 50 years, but it has several adverse effects, such as nausea, headache, vertigo, vomiting, diarrhea,
or constipation [9]. It is recommended to avoid alcohol consumption while taking this drug due to the
inhibition of aldehyde dehydrogenase. Long-term use of this drug may cause chromosomal aberrations in
Crohn’s disease [10] and occasionally peripheral neuropathy [11]. Standard treatment with metronidazole
requires 250 mg three times daily dosing for 5–7 days for giardiasis [12]. Newer metronidazole derivatives
such as tinidazole [13] and nitazoxanide, a nitrothiazolyl-salicylamide derivative [14], have fewer side-effects
and shorter treatment courses. Other drugs, such as furazolidone, albendazole, and paromomycin, are used
for giardiasis to a lesser extent with similar and/or lower success rates. Despite the efficacy of nitroimidazole
drugs, treatment failures in giardiasis have been reported in up to 40% of cases [15].
Clinical resistance of G. lamblia to metronidazole is proven and cross resistance occurs with the newer
drugs, tinidazole and nitazoxanide [16], so drug resistance is a concern with all commonly used antigiardial
drugs [16,17]. Studies on prevalence of metronidazole treatment failure for giardiasis are scarce in the USA.
Immunocompromised patients are also one of the high-risk groups for G. lamblia infection. Earlier
studies showed that individuals with HIV/AIDS were more prone to G. lamblia infection [18–21].
Considering the relative paucity of data on giardiasis and treatment failure among giardiasis patients
with HIV in the US, we carried out a single institution retrospective case series review study among G.
lamblia-infected HIV patients to determine the associated risk factors and response to primary therapy.
2. Results
2.1. Characteristics of the Study Population
We identified 29 HIV-infected patients positive for G. lamblia. All were adult males with an
average age of 43.17 ± 9.85 years and weight of 179.86 ± 26.91 lbs, as shown in Table 1. Among 29
patients, 16 were White (55.2%), 11 were Hispanic (37.9%), 1 African American (3.4%), and 1 Asian
Pacific Islander (3.4%). Though the travel history of all patients was not always available, one patient
reported exposure to dirty hurricane water while traveling to the east coast. Two patients had a travel
history of visiting Mexico. All patients were on antiretroviral treatment at time of the diagnosis.
Table 1. Characteristics of the HIV patients infected with Giardia lamblia.
Characteristics
Overall (n = 29)
No. % Average
Gender
Male 29 100
Age (Years) - - 43.17 ± 9.85
Weight (lb) - - 179.86 ± 26.91
Race/Ethnicity
White 16 55.2 -
Hispanic 11 37.9 -
African American 1 3.4 -
Asian Pacific Islander 1 3.4 -
ART (Antiretroviral Therapy)
Yes 29 100 -
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2.2. Clinical Status of Patients
For 11 patients (37.9%), both pre-diagnosis and at-diagnosis data were available. Following
diagnosis of G. lamblia infection, we found a non-statistically significant decrease in cluster of
differentiation 4 (CD4) (mean 61.38 cells/mm3 decrease, 95% CI: −25.79, 148.6, p = 0.15) and platelets
(mean 13.6 × 106/mL decrease, 95% CI: −48.38, 75.58, p = 0.63) in patients compared to the values
obtained before diagnosis of the parasitic infection, as shown in Figure 1A,B. There was a statistically
significant increase in the number of white blood cell (WBC) in G. lamblia-infected HIV patients at
the time of diagnosis compared to the WBC count before diagnosis of giardiasis (mean 2.47 × 106/mL
increase, 95% CI: −4.116, −0.8236, p = 0.008), as shown in Figure 1C. For other clinical data, the values
reported at the time of diagnosis were similar to the pre-diagnostic values. There were non-statistically
significant changes in alanine aminotransferase (ALT) (mean 3.765 U/L increase, 95% CI: −15.69, 8.161,
p = 0.51), creatinine (mean 0.046 mg/dL increase, 95% CI: −0.139, 0.046, p = 0.3), and hemoglobin (mean
0.23 g/dL increase, 95% CI: −1.62, 1.162, p = 0.72) in HIV patients between pre-diagnosis and at the
time of diagnosis of G. lamblia infection, as shown in Figure 1D–F. HIV viral load for pre-diagnosis and
at the time of diagnosis was available for only six patients. When compared, there were no statistically
significant changes in the viral load before diagnosis and at the time of diagnosis of G. lamblia (mean
752,808 copies/mL increase, 95% CI: −1,996,000, 490,041, p = 0.18), as shown in Figure 1G.
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Other symptoms included bloating, dyspepsia, and vomiting. While most patients (28 out of 29, 
96.6%) experienced diarrhea, 16 patients (55.2%) reported epigastric pain, and 15 patients (51.7%) 
showed the symptom of weight loss. Bloating, dyspepsia, and vomiting had very low frequency 
with 6.9%, 10.3%, and 13.8%, respectively, as shown in Table 2. 
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Overall (n = 29) 
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2.3. Association of Giardiasis with Symptomatology
When we studied the association ofG. lamblia infection with symptoms in HIV-infected patients, we
observed diarrhea, epigastric pain, and weight loss as the most frequent symptoms. Other symptoms
includ d bloating, dyspepsia, and vomiting. While most patients (28 out of 29, 96.6%) experienced
diarrhea, 16 ati ts (55.2%) reported epigastric pain, and 15 atients (51.7%) showed he symptom of
weight loss. Bloating, dyspeps a, and vomiting had very low frequency with 6.9%, 10.3%, and 13.8%,
respectively, as show in Table 2.
Table 2. Clinical symptoms associate it iar iasis in HIV patients.
Characteristics
Overall (n = 29)
No. %
Clinic l Symptoms
Dia rhe 28 96.6
Epigas ric Pain 16 55.2
Weight Loss 15 51.7
Bloating 2 6.9
Dyspepsia 3 10.3
Vomiting 4 13.8
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2.4. Primary Treatment of Giardiasis in HIV Patients
Most of the patients (25 patients, 86.2%) were primarily treated with metronidazole. Two patients
(6.9%) were treated with tinidazole and two patients were given ciprofloxacin (for concomitant Shigella),
as shown in Table 3. The dosing regimen for metronidazole was either 250 mg three times a day (TID)
or 500 mg TID or 500 mg two times a day (BID). The duration of treatment with metronidazole varied
between 5 days to 14 days. Two patients received 2 g once a day (QD) tinidazole; one patient was
treated with tinidazole for 7 days and another patient for one day. The patients who received 500 mg
BID ciprofloxacin also had Shigella infection, but no metronidazole was found in the electronic medical
record medication list. Only one patient reported an adverse effect due to metronidazole, with nausea
in the absence of drinking alcohol. This patient was switched to nitazoxanide at 500 mg BID for 3 days.
Table 3. Primary treatment of giardiasis in HIV patients.
Drugs
Overall (n = 29)
Dosing Regimen Duration
No. %
Metronidazole 25 86.2 250 mg three times a day (TID), 500 mgtwo times a day (BID), 500 mg TID 5–14 days
Tinidazole 2 6.9 2 g once a day (QD) 1 day, 7 days
Nitazoxanide (Switched from Metronidazole) 1 3.4 500 mg BID 3 days
Two patients who were treated successfully with primary therapy had an underlying condition
of gastroesophageal reflux disease (GERD) and one patient had Helicobacter pylori infection. Another
patient had an exposure to tuberculosis (TB) and was also positive for syphilis.
2.5. Treatment of Giardiasis with More Than One Course of Metronidazole
Out of 29 G. lamblia-positive HIV patients, 15 had follow up stool testing for the presence of G.
lamblia trophozoites or cysts and 14 patients did not. Seven patients (24.1%) were treated with more
than one course of metronidazole. The treatment courses and diagnostic testing of these seven patients
are provided in Table 4.
Several patients had comorbidities, with patient # 1 having overlapping conditions of syphilis,
shingles, and Shigella infection. Patient # 2 and 3 were suffering from hepatitis B. Patient # 3 also
experienced GERD. Patient # 6 had underlying conditions of syphilis and meningioma.
Table 4. Treatment of giardiasis in HIV patients with more than one course of drug.
Patient # Drugs Dosing Regimen Duration Treatment Follow-Up Testing
1 Metronidazole 250 mg TID 5 days After diagnosis
500 mg TID 5 days 23 days after first course oftreatment for diarrhea
11 months—Stool ova and
parasite (O&P) negative
2 Metronidazole 500 mg TID 5 days After diagnosis
500 mg TID 5 days 14 days after first course oftreatment for diarrhea N/A
500 mg TID 15 days 7 days after second course oftreatment Stool O&P negative
3 Metronidazole 500 mg TID 14 days After diagnosis
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Table 4. Cont.
Patient # Drugs Dosing Regimen Duration Treatment Follow-Up Testing
500 mg TID 10 days 3 months after first course oftreatment for diarrhea Stool O&P negative
4 Metronidazole 500 mg TID 7 days After diagnosis
500 mg BID 7 days One year after first course oftreatment for diarrhea Stool PCR positive
500 mg TID 5 days
One year and three months
after second course of
treatment
N/A
5 Metronidazole 250 mg TID 7 days After diagnosis
250 mg TID 81 days
Three and a half months after
first course of treatment for
diarrhea until resolution
N/A
6 Metronidazole 500 mg TID 5 days After diagnosis
500 mg BID 120 days
13 months and 10 days after
first course of treatment for
diarrhea
N/A
7 Metronidazole 250 mg TID 7 days After diagnosis
250 mg TID 7 days One month after first course oftreatment Stool PCR positive
Nitazoxanide 500 mg BID 4 days 4 days after second course oftreatment
Metronidazole 500 mg TID 10 days One month 10 days after thirdcourse of treatment Stool PCR positive
Tinidazole 2 g QD 1 day 4 days after fourth course oftreatment N/A
N/A—no stool testing available.
2.6. Analysis of Lab Data to Identify Predictors of Multiple Courses of Metronidazole Treatment
Since clinical data were compared only at-diagnosis level, unpaired sample T tests were performed
to compare at-diagnosis hematological, biochemical, and immunologic clinical parameters of the
patients who required more than one course of metronidazole for the treatment of giardiasis and
those who required a single course of metronidazole treatment. When WBC count was compared
between patients who required a single course of metronidazole treatment and those who required
more than one course of metronidazole, the difference was not statistically significant (p = 0.99),
as shown in Figure 2A. Similarly, non-statistically significant differences were found with platelets
(p = 0.3), as shown in Figure 2B; ALT (p = 0.78), as shown in Figure 2C; creatinine (p = 0.32),
as shown in Figure 2D; CD4 (p = 0.6), as shown in Figure 2E; and HIV viral load (p = 0.4), as shown in
Figure 2F. When the hemoglobin level at the diagnosis of G. lamblia between patients who were treated
with a single course of metronidazole treatment and those who required more than one course of
metronidazole was compared, there was a statistically significant increase in the hemoglobin (p = 0.04)
in the patients who required multiple courses of metronidazole treatment, as shown in Figure 2G.
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Figure 2. Co parison of BC (A), platelets (B), ALT (C), creatinine ( ), CD4 (E), IV viral load (F),
and hemoglobin (G) at the diagnosis level between giardiasis patients who required a single course of
metronidazole treatment and those who were treated with multiple courses of metronidazole.
3. Discussion
Though some studies were conducted earlier to assess the prevalence of G. lamblia in HIV patients,
very few were reported from the US. Our study aimed to determine the treatment regimen(s) followed
in giardiasis in HIV-infected patients and the treatment failure rates. Treatment failures of giardiasis
using metronidazole has been reported in up to 40% of cases in patients referred to the Hospital of
Tropical Diseases in London [15]. In a retrospective study, 22% of Spanish travelers who returned from
Asian countries showed refractory giardiasis [22]. Similarly, in another study in Spain, where patients
with chronic giardiasis were prospectively analyzed, about 20% were refractory to the treatment with
metronidazole or tinidazole [23,24]. Some potential factors for treatment failures may be reinfection,
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immunosuppression, resistance to the drug, insufficient drug levels, sequestration in the gallbladder or
pancreatic ducts, or co-infection with or selection of other microorganisms in the gut microbiota [23,25].
Unfortunately, there is no easy test for resistance and isolation of the strain and axenization for sterile
growth are required before resistance testing can be performed. In this 7 year retrospective single-center
chart review of giardiasis cases in HIV patients at University of California San Diego Health, we found
that most patients did not receive definitive tests of cure, so our definition of possible failure was if
patients received multiple courses of therapy. We reviewed different clinical parameters to determine
the predictors of failure from primary therapy.
We compared different hematological, biochemical, and immunological clinical data before
diagnosis and at the time of diagnosis of giardiasis in all 29 HIV patients to identify the factors
associated with giardiasis in HIV patients. We found a statistically significant increase of WBC count
at the diagnosis of giardiasis compared to the count available three to six months before diagnosis.
Although the WBC count is not consistently increased with giardiasis, our finding of increased WBC
requires further investigation to understand if it represents the impact of Giardia on patients that are
immunosuppressed, or if the increase was due to co-infection with other organisms. We also observed
decreased CD4 count in HIV patients who were diagnosed with G. lamblia infection, but this association
was not statistically significant. An earlier study also found that low CD4 counts were linked to
increased G. lamblia assemblage B replication in HIV patients [20]. When we evaluated the association
of giardiasis and the symptomatology in HIV patients, diarrhea was the most frequent clinical
manifestation. HIV patients with weakened immune systems are prone to gastrointestinal infections
and often present diarrhea for which giardia should be considered in the differential diagnosis.
Twenty (70.0%) patients were treated successfully with a single course of primary metronidazole or
tinidazole therapy. There was no consistent dose, frequency, and length of treatment used, suggesting
an educational opportunity to establish guidelines on giardia management in HIV.
Seven (24%) patients required more than one course of treatment. These seven patients were
investigated further as potential failures of primary therapy. One patient received five courses
of treatment. As a limitation for our study, it was difficult to identify the true failure rate as
the majority of the retreatment decisions (in 71% of the 7 patients) was not based on laboratory
identification of persistent infection but continued symptoms alone. In at least one case, retreatment
was based on a repeat positive multiplex PCR test, which should not be used as a test of cure,
as Giardia DNA may be detected long after resolution of infection. Again, clear guidance on
repeat testing after therapy may be needed. Almost a quarter of patients received repeat treatment,
which is not different from non-HIV-infected individuals. These findings support the need for
alternative treatment regimens for giardia. Refractory giardiasis patients were successfully treated
with metronidazole–quinacrine combination therapy in one study [25]. In two other studies, patients
with metronidazole-refractory giardiasis responded better with a combination of albendazole and
metronidazole than monotherapy [26,27]. Although the dosing, duration, and adverse effects of this
combination therapy are limited, future treatment with combinations of drugs should be studied as
second line treatment.
To determine the factors responsible for failure in primary therapy, we compared the lab data
available at the time of diagnosis between patients who were treated successfully with one round of
primary therapy and those who required multiple courses of primary therapy. Though the differences
in several clinical parameters at the diagnosis level between these two groups of patients were not
statistically significant, there was a statistically significant increase in hemoglobin in the patients who
required more than one course of metronidazole treatment compared to the patients successfully
treated with one round of metronidazole. The reason for increased hemoglobin in the patients as a
predictor of failure from primary therapy is unclear but may need further investigation.
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4. Materials and Methods
4.1. Overview
We conducted a 7 year retrospective single-center chart review to determine the prevalence of
metronidazole treatment failure for giardiasis among patients with HIV/AIDS and also to determine
the associated risk factors.
4.2. Patient Selection
Subjects who visited the largest HIV clinic, the University of California San Diego (UCSD)
Owen Clinic, between January 2011 and February 2018 were selected by having a positive test for G.
lamblia by any method. Chart records were then examined to confirm eligibility, then abstracted for
demographics, weight, recent travel, date of diagnosis, symptoms including diarrhea, weight loss,
nausea or bloating, dyspepsia, vomiting, epigastric pain, any treatment of Giardia, dosing regimen
and duration of treatment, concomitant infections, or underlying medical conditions. Records of
physical examinations focusing on the abdomen and initial laboratory testing with stools for ova
and parasite exams, results of a multiplex stool pathogen PCR (offered after September 2014), and
stool cultures for enteropathogens including Shigella, Salmonella, Campylobacter, and enterotoxigenic
Escherichia coli were collected. Stool PCR for identification of Giardia was performed using a Biofire
FilmArray Gastrointestinal (GI) Panel from bioMerieux.
The hematological, biochemical, and immunologic results were categorized into pre-diagnosis
(performed with 3–6 months prior to the positive result) and at-diagnosis (performed within two
weeks of the positive result). Pre- and at-diagnosis platelets count, WBC, hemoglobin, alanine
aminotransferase (ALT), creatinine, viral load, and CD4 count were recorded. The platelets, WBC,
and hemoglobin were measured using the XN Automated System (Sysmex, Lincolnshire, IL, USA);
ALT and creatinine were determined using a cobas c700 system (Roche, Indianapolis, IN, USA);
CD4 was counted using a FACSCanto (Becton Dickinson, San Jose, CA, USA) and HIV viral loads
were quantified using Roche HIV-1 quantitative real-time PCR run on a cobas 6800 System (Roche,
Indianapolis, IN, USA).
Treatment failure was defined both by lab confirmation of presence of Giardia in at least one of
three stool samples following therapy, and by symptoms, defined as persistence of diarrhea, bloating,
abdominal pain, or weight loss after one or more courses of metronidazole treatment. Treatment
success was defined as symptom resolution and absence of Giardia in three stool samples.
4.3. List of Inclusion Criteria
All patients met all of the following inclusion criteria. They were eligible if:
a. >18 years old
b. HIV infected
c. Giardiasis case definition by the following criteria:
i. Giardia cysts or trophozoites detected in stool by microscopic examination of wet mounts
ii. OR Giardia cysts or trophozoites identified by trichrome smear of concentrated stools
iii. OR positive stool PCR for Giardia
4.4. Data Collection
The following data were collected from the medical records:
i. Verify inclusion criteria at the time of diagnosis of Giardia
ii. Demographic data at the time of diagnosis of Giardia
iii. Travel history at the time of diagnosis and up to 90 days after diagnosis
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iv. Clinical data at the time of diagnosis and up to 90 days after diagnosis
v. Physical exam at the time of diagnosis and up to 90 days after diagnosis
vi. Lab data including microbiology, CD4, HIV viral load at the time of diagnosis and up to 90
days after diagnosis
vii. Medications including antibiotics, antiretroviral therapy (ART) at the time of diagnosis and up
to 90 days after diagnosis
Eligible patients were identified by having a positive Giardia testing with follow-up at the HIV
clinic from January 2011 to February 2018 with clinical details from the electronic medical record
(Institutional Review Board (IRB) approval (Project #180699XL, 4/26/18)).
4.5. Statistical Methods
The data entry was performed using Excel and analyzed using GraphPad Prism. Exploratory
analysis of the categorical variables was performed using percentages, and continuous variables were
presented as mean ± standard deviation. Clinical data at pre- and at-diagnosis levels were compared
using paired sample T tests with p < 0.05 as the level of statistical significance. At-diagnosis clinical
data of the patients who required more than one course of metronidazole for the treatment of giardiasis
and those who required a single course of metronidazole treatment were compared using unpaired
sample T tests. The comparison of the clinical data was visualized using box and whisker plots.
4.6. Compliance with Ethics Guidelines
The study was approved by the Institutional Review Board (IRB) of University of California San
Diego (UCSD) Human Research Protections Program (reference number: Project #180699XL, 4/26/18).
For this type of study, formal consent is not required.
5. Conclusions
In conclusion, in this case series study of giardiasis among HIV-infected individuals, we found
that clinical practice varied in diagnostic methods, treatment, and management. We observed the
failure rate for primary treatment of 24%, which is not different from non-HIV-infected individuals.
Our results support the development of giardia management guidance for HIV physicians and study
of alternative treatments.
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